BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?
No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!
 |
[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | |
Information Commissioner's Office |
||
|
You are here: BAILII >> Databases >> Information Commissioner's Office >> Medicines and Healthcare Products Regulatory Agency (Decision Notice) [2012] UKICO FS50411507 (09 January 2012) URL: http://www.bailii.org/uk/cases/UKICO/2012/FS50411507.html Cite as: [2012] UKICO FS50411507 |
||
[New search] [Printable PDF version] [Help]
Summary: The complainant requested the following: -There was a meeting held on Fri 13th May at the MHRA offices, 151 Buckingham Palace Road, concerning brand prescribing. It was chaired by Prof. Stuart Ralston representing the Commission on Human Medicines. The invitation to attend the meeting came from the MHRA. Could I have the following information about the meeting? A list of who attended and who they were representing. The agenda for the meeting. The minutes of the meeting.- The Information Commissioner-s decision is that the Medicines and Healthcare products Regulatory Agency (MHRA) correctly applied section 35(1)(a) of the FOIA (formulation or development of government policy). He considers that the public interest in maintaining the exemption outweighs the public interest in disclosing the requested information. Therefore, the MHRA is not required to disclose the information in full or in a redacted form and it is not necessary for the Information Commissioner (the Commissioner) to go on to consider the MHRA-s application of section 43(2) of the FOIA (commercial interests).
Section of Act/EIR & Finding: FOI 35 - Complaint Not upheld
